dc.creator | Provencio Pulla, M. | es |
dc.creator | Alfaro Lizaso, J. | es |
dc.creator | Cruz Merino, Luis de la | es |
dc.creator | Gumá i Padró, J. | es |
dc.creator | Quero Blanco, C. | es |
dc.creator | Gómez Codina, J. | es |
dc.creator | Llanos Muñoz, M. | es |
dc.creator | Martínez Banaclocha, N. | es |
dc.creator | Rodriguez Abreu, D. | es |
dc.creator | Rueda Domínguez, A. | es |
dc.date.accessioned | 2024-04-03T14:10:34Z | |
dc.date.available | 2024-04-03T14:10:34Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | Provencio Pulla, M., Alfaro Lizaso, J., Cruz Merino, L.d.l., Gumá i Padró, J., Quero Blanco, C., Gómez Codina, J.,...,Rueda Domínguez, A. (2015). SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma. Clinical and Translational Oncology, 17 (12), 1014-1019. https://doi.org/10.1007/s12094-015-1437-1. | |
dc.identifier.issn | 1699-048X | es |
dc.identifier.issn | 1699-3055 | es |
dc.identifier.uri | https://hdl.handle.net/11441/156646 | |
dc.description.abstract | Follicular non-Hodgkin’s lymphoma (FL) is a
nodal B lymphoid malignancy that originates from the
germinal center of a lymph node. FL is the second most
frequent lymphoma subtype. The course of the disease is
usually characterised by a typically indolent clinical
course, with a median survival rate of 8–10 years, although
most patients relapse after treatment. Diagnosis should
always be based on a surgical specimen like an excisional
node lymph biopsy. The first-line treatment of FL will
depend of extension disease, tumour burden, patient
symptoms, performance status and also patient decision.
The addition of rituximab to conventional chemotherapy
has improved ORR, PFS and OS. As first line in patients
that need treatment, a combination of chemotherapy with
rituximab induction followed by 2 years of rituximab
maintenance is the best option. High-dose chemotherapy
with autologous stem-cell transplantation in first line has
not shown improvement and is not recommended as first line therapy. Before any treatment decision in relapsed
patients, a repeat biopsy is mandatory to rule out a trans formation into large cell aggressive lymphoma. Standard
treatment is controversial, depends on the efficacy of prior
treatment, duration of the time-to-relapse, patient’s age and
histological findings at relapse. | es |
dc.format | application/pdf | es |
dc.format.extent | 6 p. | es |
dc.language.iso | eng | es |
dc.publisher | Springer | es |
dc.relation.ispartof | Clinical and Translational Oncology, 17 (12), 1014-1019. | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Oncohematology malignancies | es |
dc.subject | Follicular non-Hodgkin’s lymphoma | es |
dc.subject | Non-Hodgkin lymphoma therapy | es |
dc.title | SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma | es |
dc.type | info:eu-repo/semantics/article | es |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://link.springer.com/article/10.1007/s12094-015-1437-1 | es |
dc.identifier.doi | 10.1007/s12094-015-1437-1 | es |
dc.contributor.group | Universidad de Sevilla. CTS151: Bioquímica médica. | es |
dc.journaltitle | Clinical and Translational Oncology | es |
dc.publication.volumen | 17 | es |
dc.publication.issue | 12 | es |
dc.publication.initialPage | 1014 | es |
dc.publication.endPage | 1019 | es |